Longeveron's ELPIS II Trial for HLHS Fails Primary Endpoint

Longeveron Inc. announced that its ELPIS II Phase 2b clinical trial, evaluating the stem cell therapy laromestrocel for hypoplastic left heart syndrome (HLHS), failed to meet its primary efficacy endpoint. The investigational treatment did not improve right ventricular ejection fraction at 12 months. The company is now analyzing exploratory outcomes and intends to discuss future steps with the FDA.